Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to assess current practice patterns and barriers surrounding coordination of bispecific antibody (bsAb) step-up dosing, transitions of care, and adverse event (AE) management in eligible patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
Upon completion of this activity, participants should be better able to differentiate new and emerging bsAbs for relapsed/refractory (R/R) DLBCL and FL based on the latest clinical safety and efficacy
Upon completion of this activity, participants should be better able to align clinical practice with expert recommendations for the prompt recognition and management of AEs associated with bsAbs, including cytokine release syndrome and neurotoxicity